Stocktoria
Anbio Biotechnology NNNN
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 2025-02-19
Anbio Biotechnology statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Gross margin | 87.2% | 71.9% | 50.1% |
| Operating margin | 66.7% | 24.4% | 29.2% |
| Net margin | 74.1% | 29.0% | 33.6% |
| Return on assets | 21.2% | 12.5% | 14.3% |
| Return on equity | 21.2% | 13.8% | 15.2% |
| Current ratio | 344.31 | 10.71 | 15.86 |
| Revenue growth | 5.6% | 21.9% | — |
Source: SEC EDGAR filings · CIK 0001982708 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.